Plain-English translation of NCT07279194 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called HDM1005, given as a once-weekly injection, can help people with obesity or being overweight lose weight and improve related health problems like high blood pressure, high cholesterol, or fatty liver disease. The medication will be compared to a placebo (a dummy injection with no active medicine) over one year. All participants will also receive counseling on diet and exercise to support their weight loss efforts.
Many people struggle with weight loss and the health problems that come with it, even when they try diet and exercise alone. This trial is testing whether this new treatment could offer an additional tool to help people manage their weight more effectively.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic regularly over about 13 months for screening, baseline tests, and follow-up visits. During the 52-week treatment period, you would receive either the new medication or a placebo as a weekly injection, plus counseling on healthy eating and physical activity. After the 52 weeks of treatment, there would be a 4-week safety follow-up period. Blood tests and weight measurements would be done at various visits to track how the treatment is working and to monitor your safety.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China